Shanghai RAAS approves 2024 financials, chapter amendments

Shanghai RAAS Blood Products (SZSE:002252) announced the resolutions passed at its 2024 Annual General Meeting of Shareholders. Key approvals included the 2024 financial statements, the 2024 Board and Supervisory Committee Work Reports, the 2024 profit distribution plan, and the company's annual report. The meeting also approved revisions to the company's articles of association and rules of procedure for the board of directors. A proposal to issue letters of comfort and guarantees to related parties was passed. Resolutions were approved to conduct foreign exchange derivative transactions and using proprietary funds for cash management. The meeting was held on May 20, 2025, with 666 shareholders or their representatives attending, representing 3,099,884,062 shares, or 47.0303% of the company's total voting shares.